Pfizer – Gene and Gene-modified Cell Therapies Medical Education
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: inquire with unit
Memorial Deadline: Friday 21st, June 2024
External Deadline: Monday 1st, July 2024
Description
The mission of the American Society of Gene + Cell Therapy (ASGCT) is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease. ASGCT’s strategic vision is to be a catalyst for bringing together scientists, physicians, patient advocates, and other stakeholders to transform the practice of medicine by incorporating the use of genetic and cellular therapies to control and cure human disease.
This Request for Proposals (RFP) is for initiatives that span multiple rare disease areas. The American Society of Gene + Cell Therapy and Pfizer Global Medical Grants are collaborating to offer a new competitive grant opportunity focused on supporting independent medical education to increase the medical and scientific understanding of gene and gene-modified cell therapies.
For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.
Date RFP Issued: May 7, 2024
Geographic Scope: Global
Clinical Area: Gene Therapy – Rare Disease
Link to full RFP: Gene and Gene-Modified Cell Therapies Medical Education
Application Due Date: July 1, 2024
Specific Area of Interest: Projects that will be considered for support will focus on independent medical education initiatives that will result in the measurable improvement of the medical and scientific understanding of gene and gene-modified cell therapies to help prepare multidisciplinary teams for the integration of gene and gene-modified cell therapies into the treatment armamentarium of eligible patients with a Rare Disease.
Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Amanda Stein, Grant Officer (amanda.j.stein@pfizer.com).